<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03438552</url>
  </required_header>
  <id_info>
    <org_study_id>GETUG-AFU 31 - UC-0160/1618</org_study_id>
    <secondary_id>2017-A00008-45</secondary_id>
    <nct_id>NCT03438552</nct_id>
  </id_info>
  <brief_title>Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence</brief_title>
  <acronym>STEREO-RE-PRO</acronym>
  <official_title>Phase I/II Multi-center Study Evaluating the Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence After External Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stereo-Re-Pro aims to provide further evidence of Stereotactic Body Radiotherapy (SBRT) as a&#xD;
      supplementary non-invasive curative treatment for local recurrence following radiotherapy.&#xD;
&#xD;
      The objective of the first part of the trial (Phase I) is to select the recommended dose for&#xD;
      salvage SBRT (either 5 x 6 Gy, 6 x 6 Gy, or 5 x 5 Gy) based on dose-limiting toxicity&#xD;
      observed during the 18 weeks following the initiation of salvage-SBRT. Particular attention&#xD;
      will be paid to the quality of life and tolerance of the treatment.&#xD;
&#xD;
      The objective of the second part of the trial (phase II) is to estimate the efficacy of the&#xD;
      salvage-SBRT in terms of biochemical relapse-free survival rate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date, no standard local treatment exists for patients with an intraprostatic recurrence&#xD;
      after radiotherapy. A number of treatments options exist including: radical prostatectomy,&#xD;
      brachytherapy, High-intensity focused ultrasound (HIFU), cryotherapy, and stereotactic&#xD;
      radiotherapy. These treatments are associated with a variety of genitourinary and&#xD;
      gastrointestinal toxicities and complications. In recent years, stereotactic radiotherapy has&#xD;
      been used to treat localized prostate cancer in the primary setting but also as a salvage&#xD;
      treatment after failure of radiotherapy. The initial results of these studies are promising,&#xD;
      with respect to survival and tolerance, but further studies are required to confirm these&#xD;
      initial results.&#xD;
&#xD;
      The objective of STEREO-RE-PRO is to prospectively evaluate salvage SBRT for intraprostatic&#xD;
      recurrent prostate cancer after primary external radiotherapy. This study will select&#xD;
      patients for whom there is no standard local treatment.&#xD;
&#xD;
      After inclusion and non-inclusion criteria have been verified and the patient has consented,&#xD;
      the site will register the screening and organize the baseline visit with the placement of&#xD;
      fiducial markers within two months before the planned start of SBRT.&#xD;
&#xD;
      Once the fiducial placement has been performed and all eligibility criteria fully reviewed,&#xD;
      the site will register the patient's participation so that the bio-statistician allocates the&#xD;
      dose of SBRT. The dose will be allocated upon a model-based estimates provided by the&#xD;
      statistical team and confirmed by the trial steering committee. Five or six fractions, at a&#xD;
      level of 5 or 6 Gy per session (either 5 x 6 Gy, 6 x 6 Gy, or 5 x 5 Gy), will be delivered&#xD;
      over a maximum of 12 days to provide a total dose of 25 to 36 Gy. During the treatment phase&#xD;
      of the study, no study specific visits are scheduled and the patients will be followed as per&#xD;
      standard of care.&#xD;
&#xD;
      A follow-up visit is planned at 6, 10, 18 weeks from the start of SBRT for safety evaluation.&#xD;
      Subsequent follow-up visits are planned at 6, 9, 12, 18, 24, 30, and 36 months after the&#xD;
      start of radiotherapy. Thereafter, yearly follow-up visits at 48, 60, and 72 months after&#xD;
      starting SBRT will be planned after the initial 3-year follow-up period. M72 visit&#xD;
      corresponds to the end of study visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2018</start_date>
  <completion_date type="Anticipated">November 2027</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Selection of the recommended dose for salvage-SBRT (either 5 x 6 Gy, 6 x 6 Gy, or 5 x 5 Gy) based on dose-limiting toxicity observed during the 18 weeks following the initiation of salvage-SBRT.</measure>
    <time_frame>18 weeks</time_frame>
    <description>The dose-escalation part of the study will terminate once 10 patients have been treated and evaluated at a dose currently identified as the recommended dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimate the efficacy of the salvage-SBRT in terms of biochemical relapse-free survival rate</measure>
    <time_frame>6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of acute and late genitourinary toxicities of the salvage-SBRT</measure>
    <time_frame>3 years</time_frame>
    <description>Acute and late genitourinary toxicities over the first 3 years according to the NCI-CTCAE V4.03 classification (June 14th, 2010)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the efficacy of the salvage-SBRT in terms of clinical progression-free survival and overall survival</measure>
    <time_frame>6 years</time_frame>
    <description>Clinical progression-free survival is defined as the time interval between the date of registration and the date of clinical progression (local progression assessed by the physical examination, or appearance of metastatic lesions) or death irrespective of the cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Quality of life after salvage-SBRT</measure>
    <time_frame>6 years</time_frame>
    <description>Quality of life will be evaluated based on the EORTC QLQ-C30. The Time Until Definitive Deterioration (TUDD) will be computed from registration until the first observation of a definitive deterioration of the quality of life, defined as a score decreased by 10 points (in the case of global health scale and functional scales) or increased by 10 points (in the case of symptom scales) compared to the score at baseline, without later improvement superior to 10 points compared to baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Quality of life after salvage-SBRT</measure>
    <time_frame>6 years</time_frame>
    <description>Quality of life will be evaluated based on the EORTC QLQ-PR25. The Time Until Definitive Deterioration (TUDD) will be computed from registration until the first observation of a definitive deterioration of the quality of life, defined as a score decreased by 10 points (in the case of global health scale and functional scales) or increased by 10 points (in the case of symptom scales) compared to the score at baseline, without later improvement superior to 10 points compared to baseline score.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Local Recurrence of Malignant Tumor of Prostate</condition>
  <arm_group>
    <arm_group_label>SBRT at a total dose of 30 Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placement of fiducials marker seeds in the prostate followed by the administration of stereotactic body radiotherapy at 30 Gy (5 sessions at a level of 6 Gy each- 1 session per day) 30 Gy is the first dose-level. During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SBRT at a total dose of 25 Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placement of fiducials marker seeds in the prostate followed by the administration of stereotactic body radiotherapy at 25 Gy (5 sessions at a level of 5 Gy each- 1 session per day) During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SBRT at a total dose of 36 Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placement of fiducials marker seeds in the prostate followed by the administration of stereotactic body radiotherapy at 36 Gy (6 sessions at a level of 6 Gy each- 1 session per day) During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiotherapy</intervention_name>
    <description>This radiotherapy may be administered with the CyberKnife® or a linear accelerator allowing stereotactic radiotherapy.</description>
    <arm_group_label>SBRT at a total dose of 25 Gy</arm_group_label>
    <arm_group_label>SBRT at a total dose of 30 Gy</arm_group_label>
    <arm_group_label>SBRT at a total dose of 36 Gy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biochemical recurrence occurring at least 2 years after external radiotherapy for&#xD;
             prostatic adenocarcinoma by the Phoenix definition (PSA nadir + 2 ng/mL)&#xD;
&#xD;
          -  T1-T2c and PSA ≤20 ng/mL and Gleason score ≤7 at initial diagnosis of prostate cancer&#xD;
             before the initial/first treatment.&#xD;
&#xD;
          -  Recurrence of prostatic adenocarcinoma proven by histology following radiotherapy by&#xD;
             transrectal or transperineal sextant biopsies of the two lobes of the prostate, with a&#xD;
             minimum of 12 biopsies, irrespective of Gleason score. Biopsies of the seminal&#xD;
             vesicles are optional.&#xD;
&#xD;
          -  Clinical stage T1-T2 on relapse; unilateral extracapsular extension (T3a) on MRI&#xD;
             permitted except posteriorly relative to the rectum&#xD;
&#xD;
          -  Estimated clinical target volume (CTV) / prostate volume &lt; 0.5 based on imaging and&#xD;
             biopsies&#xD;
&#xD;
          -  Pelvic and prostatic assessment by multiparametric MRI- Absence of pelvic or&#xD;
             metastatic recurrence proven by choline PET scan&#xD;
&#xD;
          -  Performance status World Health Organization (WHO) 0-1&#xD;
&#xD;
          -  PSA level ≤10 ng/mL at baseline (before salvage-SBRT)&#xD;
&#xD;
          -  PSA doubling time &gt;10 months&#xD;
&#xD;
          -  International Prostate Cancer Score (IPSS) ≤12&#xD;
&#xD;
          -  Uroflowmetry with a maximum flow rate &gt;10 mL/s, a postvoid residual urine volume &lt;150&#xD;
             mL, and a urine volume &gt;150 mL.&#xD;
&#xD;
          -  No other anti-cancer treatment since the external radiotherapy administered as&#xD;
             first-line treatment&#xD;
&#xD;
          -  No other anti-cancer treatment planned for the current recurrence&#xD;
&#xD;
          -  No contraindication to fiducial marker implants; haemostatic disorders must be&#xD;
             corrected before implantation&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Life-expectancy greater than or equal to 5 years (Lee scale)&#xD;
&#xD;
          -  Patient registered with a health insurance system&#xD;
&#xD;
          -  Patient who has signed the informed consent form&#xD;
&#xD;
          -  Patients willing and able to comply with the scheduled visits, treatment plan,&#xD;
             laboratory tests, and other study procedures indicated in the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lymph node or metastatic spread&#xD;
&#xD;
          -  Late post-radiotherapy urinary or gastrointestinal toxicity of grade ≥2 (following&#xD;
             primary radiotherapy)&#xD;
&#xD;
          -  Other cancers in the last 5 years except for non-melanoma-type skin cancer&#xD;
&#xD;
          -  History of inflammatory bowel disease&#xD;
&#xD;
          -  Anticoagulant treatment&#xD;
&#xD;
          -  Contraindications to undergoing MRI&#xD;
&#xD;
          -  Prostate volume &gt;80 cc&#xD;
&#xD;
          -  Transurethral resection of the prostate (TURP) in the 6 months before registrations&#xD;
&#xD;
          -  Presence of rectal telangiectasia grade 3 classified by the Vienna Rectoscopy Score&#xD;
             (obligatory rectoscopy)&#xD;
&#xD;
          -  Previous rectal surgery&#xD;
&#xD;
          -  Patients unable to undergo medical follow-up in the study for geographical, social or&#xD;
             psychological&#xD;
&#xD;
          -  Person deprived of their liberty or under protective custody or guardianship&#xD;
&#xD;
          -  Patients enrolled in another therapeutic study&#xD;
&#xD;
        All patients during the SBRT planning with a ratio of clinical target volume (CTV) /&#xD;
        prostate volume &gt;0.5 will be withdrawn from the study. These patients will be considered as&#xD;
        not evaluable and will not be treated within the context of the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Pasquier</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret, LILLE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Soazig NENAN</last_name>
    <phone>+33 (0)185 343 113</phone>
    <email>s-nenan@unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meryem BRIHOUM</last_name>
    <phone>+33 (0)180 501 295</phone>
    <email>m-brihoum@unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel MEYER</last_name>
      <phone>+33(0)231 455 002</phone>
      <email>e.meyer@baclesse.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel MEYER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geneviève LOOS</last_name>
      <phone>+33(0)473 278 142</phone>
      <email>genevieve.loos@clermont.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Geneviève LOOS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre George François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magali QUIVRIN</last_name>
      <phone>+33 (0)380 737 518</phone>
      <email>mquivrin@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>Magali QUIVRIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David PASQUIER</last_name>
      <phone>+ 33(0) 320 295 911</phone>
      <email>d-pasquier@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>David PASQUIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal POMMIER</last_name>
      <phone>+33(0)478 785 166</phone>
      <email>pascal.pommier@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Pascal Pommier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut régional du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298 CEDEX 05</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David AZRIA</last_name>
      <phone>+33(0)467 613 132</phone>
      <email>david.azria@icm.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>David AZRIA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe MAINGON</last_name>
      <phone>+33(0)184 827 276</phone>
      <email>philippe.maingon@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe MAINGON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane GUERIF</last_name>
      <phone>+33(0)549 444 485</phone>
      <email>stephane.guerif@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane GUERIF</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DE CREVOISIER Renaud</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renaud DE CREVOISIER</last_name>
      <phone>+33(0)299 253 046</phone>
      <email>r.de-crevoisier@rennes.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Renaud DE CREVOISIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO -Site René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephane SUPIOT</last_name>
      <phone>+33 (0)240 679 900</phone>
      <email>stephane.supiot@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Stephane SUPIOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas MAGNE</last_name>
      <phone>+33(0)477 917 104</phone>
      <email>nicolas.magne@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas MAGNE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Henry S.Kaplan</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume JANORAY</last_name>
      <phone>+33(0)2 47 47 82 65</phone>
      <email>g.janoray@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Guillaume JANORAY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier PEIFFERT</last_name>
      <phone>+33(0)3 83 59 84 31</phone>
      <email>d.peiffert@nancy.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Didier PEIFFERT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>February 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

